GBT and Sickle Cell Disease Association of America to Host 9th Annual Sickle Cell Disease (SCD) Therapeutics Conference
September 09 2020 - 8:00AM
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) and
the Sickle Cell Disease Association of America,
Inc. (SCDAA) will host the 9th Annual Sickle Cell
Disease (SCD) Therapeutics Conference on Tuesday,
September 15. The virtual conference, which takes place during
National Sickle Cell Awareness Month, is open to the public and
will be livestreamed on the SCD Therapeutics Conference website and
the Facebook page of Sickle Cell Warriors, an SCD community
organization.
Admiral Brett P. Giroir, M.D., Assistant Secretary for Health of
the U.S. Department of Health and Human Services, will deliver the
keynote address. The event will feature discussions about the
latest advances and future trends in the treatment of SCD, and the
impact of COVID-19 on this vulnerable patient population.
“As a community, we have made tremendous progress in advancing
the treatment of SCD in recent years. However, people with SCD
continue to be misunderstood, mistreated, and fail to receive the
care they deserve. We have a responsibility to improve health
outcomes for the SCD community,” said Ted W. Love, M.D., president
and CEO of GBT. “The SCD Therapeutics Conference, which we are
honored to co-host with SCDAA, will bring together members of
the SCD community to discuss the future of SCD care and ways we can
make a lasting impact on how individuals with SCD are seen and
treated.”
The program will include panel discussions featuring leading
physicians from around the world, patients, advocates, and policy
makers, as well as updates from GBT’s 2020 Access to Excellent Care
for Sickle Cell Patients (ACCEL) Grant recipients, who are focused
on delivering high-quality healthcare to people living with
SCD.
“We are privileged to unite industry leaders from around the
world to highlight important and timely topics such as the impact
of COVID-19 and how patients, caregivers, and healthcare providers
can best manage care in light of the ongoing challenges posed by
the pandemic,” said Beverley Francis-Gibson, president and CEO of
the SCDAA. “The conference will provide a critical platform for the
SCD community to learn, share, and discuss SCD-related topics,
issues, and solutions.”
The 9th Annual SCD Therapeutics Conference will
feature the following speakers and panelists:
- Biree Andemariam, M.D., Chief Medical Officer, SCDAA
- Nnenna Badamosi, M.D., M.P.H., Director, Augusta University
Sickle Cell Program
- Kevin Baxter, Sickle Cell Patient Advocate
- Mary Bentley LaMar, Founder and Executive Director, The Sickle
Cell Association of New Jersey
- Raffaella Colombatti, M.D., Ph.D., Physician Azienda,
Ospedaliera-Università di Padova
- Lori Crosby, Psy.D., Professor, University of Cincinnati
Department of Pediatrics, Cincinnati Children’s Hospital Medical
Center
- Beverley Francis-Gibson, M.A., President and CEO, SCDAA
- Admiral Brett P. Giroir, M.D., Assistant Secretary for Health,
U.S. Department of Health and Human Services
- Kristina Harrell, M.D., M.S., Pediatric Hematology and
Oncology, Levine Children’s Blood Disorders Clinic, Atrium
Health
- Dima Hendricks, Sickle Cell Patient Advocate
- Dennis McCullum, Sickle Cell Patient
- Shirley Miller, M.A., Sickle Cell National Patient
Advocate
- Kay Saving, M.D., Professor and Division Head, OSF HealthCare,
Children’s Hospital of Illinois
- Aimee Smith, Ph.D., Assistant Professor, East Carolina
University Comprehensive Sickle Cell Program
Additionally, multiple companies that are developing treatments
for patients with SCD will present at the conference. They include
Agios Pharmaceuticals, Bluebird Bio, Cyclerion Therapeutics, GBT,
Imara, Inc., and Vertex Pharmaceuticals/CRISPR Therapeutics.
For more information about the conference or to register to
attend, visit http://www.scdconference.com. Follow the
conversation on Twitter using the hashtag #SCDTC. After the event,
GBT will post videos on its corporate YouTube channel.
About Sickle Cell Disease Sickle cell disease
(SCD) affects an estimated 100,000 people in the United
States and millions of people throughout the world,
particularly among those whose ancestors are from sub-Saharan
Africa.1 It also affects people of Hispanic, South Asian,
Southern European, and Middle Eastern ancestry.1 SCD is a
lifelong inherited blood disorder that impacts hemoglobin, a
protein carried by red blood cells that delivers oxygen to tissues
and organs throughout the body.2 Due to a genetic mutation,
people with SCD form abnormal hemoglobin known as sickle
hemoglobin. Through a process called hemoglobin polymerization, red
blood cells become sickled – deoxygenated, crescent-shaped, and
rigid.2-4 The sickling process causes hemolytic anemia (low
hemoglobin due to red blood cell destruction) and blockages in
capillaries and small blood vessels, which impede the flow of blood
and oxygen throughout the body. The diminished oxygen delivery to
tissues and organs can lead to life-threatening complications,
including stroke and irreversible organ damage.4-6
About Global Blood TherapeuticsGlobal
Blood Therapeutics (GBT) is a biopharmaceutical company
dedicated to the discovery, development, and delivery of
life-changing treatments that provide hope to underserved patient
communities. Founded in 2011, GBT is delivering on its goal to
transform the treatment and care of sickle cell disease (SCD), a
lifelong, devastating inherited blood disorder. The company has
introduced Oxbryta® (voxelotor), the first FDA-approved
treatment that directly inhibits sickle hemoglobin polymerization,
the root cause of red blood cell sickling in SCD. GBT is also
advancing its pipeline program in SCD with inclacumab, a p-selectin
inhibitor in development to address pain crises associated with the
disease. In addition, GBT’s drug discovery teams are working on new
targets to develop the next generation of treatments for SCD. To
learn more, please visit www.gbt.com and follow the
company on Twitter @GBT_news.
About SCDAASCDAA’s mission is: To advocate for
people affected by sickle cell conditions and empower
community-based organizations to maximize quality of life and raise
public consciousness while advancing the search for a universal
cure. Visit www.sicklecelldisease.org.
References
- Centers for Disease Control and
Prevention website. Sickle Cell Disease
(SCD). https://www.cdc.gov/ncbddd/sicklecell/data.html.
Accessed June 3, 2019.
- National Heart, Lung, and Blood Institute website.
Sickle Cell
Disease. https://www.nhlbi.nih.gov/health-topics/sickle-cell-disease.
Accessed August 5, 2019.
- Rees DC, et al. Lancet. 2010;376(9757):2018-2031.
- Kato GJ, et al. Nat Rev Dis Primers. 2018;4:18010.
- Kato GJ, et al. J Clin Invest. 2017;127(3):750-760.
- Caboot JB, et al. Paediatr Respir Rev.
2014;15(1):17-23.
GBT Contact Information:Steven Immergut
(media)650-410-3258simmergut@gbt.com
Stephanie Yao (investors)650-741-7730syao@gbt.com
SCDAA Contact Information:Emma
Dayeday@sicklecelldisease.org
Kyri Jacobskjacobs@sicklecelldisease.org
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Sep 2023 to Sep 2024